Pharmaceuticals, Biotechnology and Life Sciences
Cellectis has had first patient dosed with off-the-Shelf UCARTCS1 product candidate for relapsed/refractory multiple myeloma.
Verastem Oncology has reported $9 Million in total revenue, including $4.0 Million in net product revenue from COPIKTRA®; Reaffirms FY2019…
Seattle Genetics has record Adcetris net sales in U.S. and Canada of $167.6 Million in the third quarter, an increase…
SY-5609 Shows Robust Anti-Tumor Activity in Lung, Breast and Ovarian Cancer Models Deeper and More Sustained Responses Associated with RB…
Data from a phase 1 clinical trial suggest that circulating tumor DNA (ctDNA) may serve as a reliable biomarker of…
CROs eliminating manual processes and modernizing systems to streamline information exchange and accelerate study start-up BARCELONA, Spain–(BUSINESS WIRE)–Contract research organizations…
– Median Progression Free Survival (mPFS) of 46 Weeks for the Second-Line Gastrointestinal Stromal Tumors (GIST) Cohort from the Phase…
– Median Progression Free Survival (mPFS) of 46 Weeks for the Second-Line Gastrointestinal Stromal Tumors (GIST) Cohort from the Phase…
Former Cigna & Express Scripts Senior Attorney Joins Leading Digital Health Company Reducing Pharmaceutical Costs for Patients NEW YORK–(BUSINESS WIRE)–Blink…
Life Sciences Trade Groups Warn Congress: International Reference Pricing Proposals Included in Bills Like H.R. 3 Undermine Hope for Patients…